Results 201 to 210 of about 31,424 (285)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies. [PDF]

Front Oncol
Aqil MS, Al-Marrawi Y, Yaldo M, Abu-Mahfouz A, Singh L, Gopishetty S, Idogun P, Ezekwudo D, Jaiyesimi I, Weiner AJ.   +9 more
europepmc   +1 more source

Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review

Drug and Alcohol Review, Volume 45, Issue 4, May 2026.
ABSTRACT Issues Higher delta‐9‐tetrahydrocannabinol (THC) concentration medicinal cannabis products are characterised by a higher THC and minimal cannabidiol (CBD) content. This rapid review aims to systematically summarise and evaluate the available evidence regarding the efficacy and safety of higher THC potency medicinal cannabis products relevant ...
Myfanwy Graham, Dereje Assefa, Ngo Cong‐Lem, Suzanne Nielsen   +3 more
wiley   +1 more source

CL-EVLPs Promote Corneal Repair in a BAC-Induced Corneal Injury Model via Ocular Microenvironment Reconstruction. [PDF]

Invest Ophthalmol Vis Sci
Fu M, Peng D, Xu Y, Zhang Y, Chen Y, Shao Q, Chi ZL.   +6 more
europepmc   +1 more source

Comparison of clinical and inflammatory markers for dry eye disease following phacoemulsification and manual small incision cataract surgery (MSICS). [PDF]

Sci Rep
Behera G, Ramachandar H, Rajappa M, Babu KR.   +3 more
europepmc   +1 more source

Impact of Dry Eye Disease and Lipid-Containing Artificial Tears on Keratometric Reproducibility and Intraocular Lens Calculation in Cataract Patients. [PDF]

Medicina (Kaunas)
Lacmanović Lončar V, Mikulić D, Aljinović-Vučić V, Vatavuk Z, Petric Vicković I.   +4 more
europepmc   +1 more source

Immuno-inflammatory axis of menopausal dry eye: from hormonal fluctuations to ocular surface dysregulation. [PDF]

Front Immunol
Tian ZT, Jing CY, Liu HB, Jia XK, Xu HY, Pang YY.   +5 more
europepmc   +1 more source

Mitigation of Oxidative Stress Pathways in the Diabetic Cornea and Lacrimal Glands Contributes to the Rapid Reversal of Diabetic Dry Eye by Naltrexone. [PDF]

Invest Ophthalmol Vis Sci
Krebs AK, Diaz D, Sassani JW, Zagon IS, McLaughlin PJ.   +4 more
europepmc   +1 more source

Characteristics of the meibomian gland in a population without dry eye symptoms. [PDF]

Sci Rep
Kengpunpanich S, Prabhasawat P, Jongpipatchai R, Chirapapaisan C, Ngowyutagon P, Booranapong W.   +5 more
europepmc   +1 more source

Central Nervous System Mechanisms and Treatment Response in Chronic Ocular Surface Pain: Protocol for a Cross-Sectional Observational Phenotyping Study.

JMIR Res Protoc
De Lott LB, Harte SE, Kaplan C, Williams DA, Shtein R, Woodward MA, Tsodikov A, Deveney T, Galor A, Shea A, Schultz C, McKolay C, Scott KA, Clauw DJ.   +13 more
europepmc   +1 more source